Drug Approval | May 24, 2022
Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Objective tracking data combined with cohort data to drive medicine of the future
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
Risk management plans can serve as a safeguard, helping manufacturers prepare for and respond to hazards that could lead to drug supply disruptions and shortages
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
This new fund is amongst the largest for the sector in India
Multiples is the first private equity (PE) investor in the company
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
Subscribe To Our Newsletter & Stay Updated
